[go: up one dir, main page]

CL2014002796A1 - Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal. - Google Patents

Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.

Info

Publication number
CL2014002796A1
CL2014002796A1 CL2014002796A CL2014002796A CL2014002796A1 CL 2014002796 A1 CL2014002796 A1 CL 2014002796A1 CL 2014002796 A CL2014002796 A CL 2014002796A CL 2014002796 A CL2014002796 A CL 2014002796A CL 2014002796 A1 CL2014002796 A1 CL 2014002796A1
Authority
CL
Chile
Prior art keywords
polymeric material
attacks
intestinal
susceptible
delayed
Prior art date
Application number
CL2014002796A
Other languages
English (en)
Inventor
González Roberto Carlos Bravo
Thomas Buser
Frédéric Jean-Claude Goutte
Abdul Waseh Basit
Felipe José Oliveria Varum
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CL2014002796A1 publication Critical patent/CL2014002796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Grain Derivatives (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002796A 2012-04-30 2014-10-17 Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal. CL2014002796A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
CL2014002796A1 true CL2014002796A1 (es) 2015-02-06

Family

ID=46025554

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014002795A CL2014002795A1 (es) 2012-04-30 2014-10-17 Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.
CL2014002796A CL2014002796A1 (es) 2012-04-30 2014-10-17 Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014002795A CL2014002795A1 (es) 2012-04-30 2014-10-17 Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion.

Country Status (41)

Country Link
US (6) US9364440B2 (es)
EP (6) EP2659881B1 (es)
JP (2) JP6621662B2 (es)
KR (6) KR102102198B1 (es)
CN (5) CN104302274A (es)
AR (1) AR090898A1 (es)
AU (4) AU2013255914B2 (es)
BR (3) BR112014026933B1 (es)
CA (4) CA3080035A1 (es)
CL (2) CL2014002795A1 (es)
CO (2) CO7151506A2 (es)
CR (4) CR20190246A (es)
CU (1) CU24304B1 (es)
CY (4) CY1120215T1 (es)
DK (5) DK2659881T3 (es)
EA (2) EA032811B1 (es)
ES (6) ES2655622T3 (es)
GE (4) GEP201706759B (es)
HR (2) HRP20180068T1 (es)
HU (5) HUE036187T2 (es)
JO (6) JOP20200144A1 (es)
LT (5) LT2659881T (es)
ME (2) ME03364B (es)
MX (4) MX362529B (es)
MY (3) MY169161A (es)
NO (1) NO2659881T3 (es)
NZ (3) NZ725409A (es)
PE (3) PE20190625A1 (es)
PH (2) PH12014502339A1 (es)
PL (5) PL2659881T3 (es)
PT (5) PT2659881T (es)
RS (5) RS56839B1 (es)
SA (2) SA115370043B1 (es)
SG (2) SG11201406798WA (es)
SI (5) SI2659881T1 (es)
SM (5) SMT201800095T1 (es)
TN (2) TN2014000442A1 (es)
TR (3) TR201905226T4 (es)
TW (3) TWI618547B (es)
UY (1) UY34772A (es)
WO (2) WO2013164315A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2659881T3 (pl) * 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
HRP20190470T1 (hr) * 2012-04-30 2019-05-17 Tillotts Pharma Ag Formulacija lijeka s odgođenim otpuštanjem
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
KR102167265B1 (ko) * 2013-02-22 2020-10-19 제리아 신야쿠 고교 가부시키 가이샤 장용정
JP6273356B2 (ja) 2013-10-29 2018-01-31 ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ 遅延放出性薬物製剤
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
WO2018102469A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
WO2019183208A1 (en) * 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
AU2019239300A1 (en) * 2018-03-23 2020-11-19 Palatin Technologies, Inc. Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES3002632T3 (en) * 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3666262B1 (en) * 2018-12-10 2021-11-10 Aphaia IP AG Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
KR20220046623A (ko) * 2019-08-12 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 치료제의 투여를 위한 물품 및 방법
US20230301927A1 (en) * 2019-11-13 2023-09-28 Ethypharm Process for producing an orally administered pharmaceutical composition with colonic delivery
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
WO2022014601A1 (ja) * 2020-07-13 2022-01-20 キリンホールディングス株式会社 フィルムコーティング錠剤
US20240293429A1 (en) * 2021-06-01 2024-09-05 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
CN117024341A (zh) * 2022-04-30 2023-11-10 宁波大学 一类d-2a不对称型热活化延迟荧光材料的合成及其应用
CN116898823A (zh) * 2023-08-02 2023-10-20 中国农业大学 一种微囊结构及其制备方法和应用
WO2025082972A1 (en) * 2023-10-16 2025-04-24 Bioprojet Pharma Enteric coated pitolisant formulations and methods of use
CN118806729B (zh) * 2024-06-18 2025-04-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法
WO2026003735A1 (en) * 2024-06-28 2026-01-02 Università Degli Studi Di Milano Oral platform for site-specific release to the colon
EP4674409A1 (en) * 2024-07-04 2026-01-07 Roquette Freres Oral tablets for the colonic delivery of therapeutic proteins
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1108431B1 (en) * 1999-12-16 2003-05-02 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR20030097892A (ko) 2001-05-25 2003-12-31 에스에스 세야쿠 가부시키 가이샤 의약 배합제
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2008543929A (ja) 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
WO2008068584A2 (en) * 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
WO2008117814A1 (ja) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
ES2759626T3 (es) * 2007-05-07 2020-05-11 Evonik Operations Gmbh Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
AU2010260129B2 (en) 2009-06-15 2014-05-29 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
KR101573889B1 (ko) * 2009-10-09 2015-12-04 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
PL2659881T3 (pl) * 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
JP6273356B2 (ja) 2013-10-29 2018-01-31 ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ 遅延放出性薬物製剤

Also Published As

Publication number Publication date
SG11201406799XA (en) 2014-11-27
EP2844220B1 (en) 2019-01-23
SA115370043B1 (ar) 2016-05-24
JO3574B1 (ar) 2020-07-05
JOP20200146A1 (ar) 2022-10-30
JOP20200148A1 (ar) 2022-10-30
CR20140486A (es) 2015-01-19
PT2844220T (pt) 2019-03-27
CN104271113B (zh) 2019-03-22
CA2871016A1 (en) 2013-11-07
AU2013255914B2 (en) 2017-08-31
EA032514B1 (ru) 2019-06-28
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
JOP20200145B1 (ar) 2023-09-17
EA201491781A1 (ru) 2014-12-30
JOP20200145A1 (ar) 2022-10-30
GEP201706736B (en) 2017-09-25
DK2844222T3 (da) 2019-12-09
CN110237056B (zh) 2022-03-08
US10272048B2 (en) 2019-04-30
BR112014026933A2 (pt) 2017-06-27
CO7151506A2 (es) 2014-12-29
EP2844222A1 (en) 2015-03-11
DK3189830T3 (en) 2018-07-16
CN104302274A (zh) 2015-01-21
US20170035698A1 (en) 2017-02-09
ES2720258T3 (es) 2019-07-19
HUE046628T2 (hu) 2020-03-30
TN2014000441A1 (en) 2016-03-30
LT3278792T (lt) 2019-05-10
CR20190246A (es) 2019-09-03
HUE037702T2 (hu) 2018-09-28
CA3052460A1 (en) 2013-11-07
US11534406B2 (en) 2022-12-27
RS58625B1 (sr) 2019-05-31
KR20200073296A (ko) 2020-06-23
SI2844222T1 (sl) 2020-02-28
CO7141433A2 (es) 2014-12-12
US20150132380A1 (en) 2015-05-14
CY1120215T1 (el) 2018-12-12
CL2014002795A1 (es) 2015-02-13
SMT201800095T1 (it) 2018-03-08
TWI700102B (zh) 2020-08-01
ES2655622T3 (es) 2018-02-20
TR201905226T4 (tr) 2019-05-21
TW202037370A (zh) 2020-10-16
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
EP3189830B1 (en) 2018-05-23
JP2015515965A (ja) 2015-06-04
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
TW201720430A (zh) 2017-06-16
NZ629260A (en) 2017-01-27
WO2013164316A1 (en) 2013-11-07
KR102104070B1 (ko) 2020-04-24
PL3189830T3 (pl) 2018-11-30
EP3189830A1 (en) 2017-07-12
GEP201706758B (en) 2017-10-25
MX373249B (es) 2020-05-12
BR122019022551B1 (pt) 2022-07-19
DK2659881T3 (en) 2018-02-05
CN110200949A (zh) 2019-09-06
AU2017210571A1 (en) 2017-08-24
ME03641B (me) 2020-07-20
SI2844220T1 (sl) 2019-05-31
CN110237056A (zh) 2019-09-17
HUE042833T2 (hu) 2019-07-29
PT3189830T (pt) 2018-10-19
CY1122475T1 (el) 2021-01-27
CN110200949B (zh) 2021-11-16
EP2844222B1 (en) 2019-11-13
CA2871017A1 (en) 2013-11-07
TR201809416T4 (tr) 2018-07-23
SMT201900252T1 (it) 2019-07-11
CY1120492T1 (el) 2019-07-10
AU2013255914A1 (en) 2014-11-13
JOP20200144A1 (ar) 2017-06-16
PL2844222T3 (pl) 2020-03-31
SG11201406798WA (en) 2014-11-27
RS59697B1 (sr) 2020-01-31
AU2013255913A1 (en) 2014-11-13
ME03364B (me) 2019-10-20
KR102177773B1 (ko) 2020-11-12
GEP201706759B (en) 2017-10-25
US20140056980A1 (en) 2014-02-27
TR201903569T4 (tr) 2019-04-22
PT3278792T (pt) 2019-05-23
JOP20200146B1 (ar) 2023-09-17
US10226430B2 (en) 2019-03-12
JP6621661B2 (ja) 2019-12-18
AU2013255913B2 (en) 2017-08-31
US20200214987A1 (en) 2020-07-09
RS58735B1 (sr) 2019-06-28
EP2659881A1 (en) 2013-11-06
ES2673931T3 (es) 2018-06-26
PE20150129A1 (es) 2015-02-13
MX366677B (es) 2019-07-19
UY34772A (es) 2013-11-29
NZ725409A (en) 2018-05-25
PH12014502339B1 (en) 2014-12-22
AR090898A1 (es) 2014-12-17
KR20190127984A (ko) 2019-11-13
EP2844220A1 (en) 2015-03-11
CR20190245A (es) 2019-07-29
SMT202000014T1 (it) 2020-03-13
LT2659881T (lt) 2018-02-12
PL2659881T3 (pl) 2018-05-30
DK3278792T3 (da) 2019-05-06
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
CU20140123A7 (es) 2015-02-26
PT2659881T (pt) 2018-01-29
JP6621662B2 (ja) 2019-12-18
TW201343202A (zh) 2013-11-01
KR20190127986A (ko) 2019-11-13
LT3189830T (lt) 2018-07-10
DK2844220T3 (en) 2019-04-08
US20170266117A1 (en) 2017-09-21
LT2844220T (lt) 2019-04-10
EP3187171C0 (en) 2024-09-25
MX2014012887A (es) 2015-05-08
CR20140485A (es) 2015-01-19
WO2013164315A1 (en) 2013-11-07
TN2014000442A1 (en) 2016-03-30
CN106983735A (zh) 2017-07-28
CU24304B1 (es) 2018-01-10
KR20200075024A (ko) 2020-06-25
ES2714448T3 (es) 2019-05-28
NO2659881T3 (es) 2018-04-28
CY1121609T1 (el) 2020-05-29
KR102102198B1 (ko) 2020-04-21
KR20150004910A (ko) 2015-01-13
KR20150004911A (ko) 2015-01-13
BR112014026933B1 (pt) 2022-07-19
PH12014502340B1 (en) 2014-12-22
TWI618547B (zh) 2018-03-21
AU2017210571B2 (en) 2018-11-29
PE20190625A1 (es) 2019-04-26
MX367127B (es) 2019-08-06
TWI705833B (zh) 2020-10-01
EP3187171B1 (en) 2024-09-25
SI3189830T1 (en) 2018-08-31
GEP201706753B (en) 2017-10-25
AU2017210577B2 (en) 2018-11-29
PH12014502340A1 (en) 2014-12-22
PE20142442A1 (es) 2015-01-28
SI3278792T1 (sl) 2019-06-28
HUE036187T2 (hu) 2018-06-28
RS56839B1 (sr) 2018-04-30
EA032811B1 (ru) 2019-07-31
LT2844222T (lt) 2019-12-27
JP2015515964A (ja) 2015-06-04
US9814681B2 (en) 2017-11-14
EP3187171A1 (en) 2017-07-05
NZ629262A (en) 2017-01-27
PT2844222T (pt) 2019-12-30
MY169161A (en) 2019-02-19
MY190392A (en) 2022-04-20
SMT201800360T1 (it) 2018-09-13
BR112014026935A2 (pt) 2017-06-27
HUE043238T2 (hu) 2019-08-28
US9364440B2 (en) 2016-06-14
CA2871016C (en) 2023-03-21
CN104271113A (zh) 2015-01-07
ES2987408T3 (es) 2024-11-14
US11517534B2 (en) 2022-12-06
US20150125525A1 (en) 2015-05-07
EA201491783A1 (ru) 2014-12-30
JOP20200147A1 (ar) 2022-10-30
AU2017210577A1 (en) 2017-08-24
MX362529B (es) 2019-01-23
HRP20180965T1 (hr) 2018-08-10
CA3052460C (en) 2022-06-07
PL3278792T3 (pl) 2019-09-30
CA3080035A1 (en) 2013-11-07
EP3278792B1 (en) 2019-02-20
RS57431B1 (sr) 2018-09-28
ES2761341T3 (es) 2020-05-19
SMT201900215T1 (it) 2019-05-10
PH12014502339A1 (en) 2014-12-22
JOP20200148B1 (ar) 2023-09-17
EP3278792A1 (en) 2018-02-07
JOP20200147B1 (ar) 2023-09-17

Similar Documents

Publication Publication Date Title
CL2014002796A1 (es) Formulación de fármaco de liberación retardada que comprende una capa externa formada por una mezcla de un primer material polimerico que es suceptible ataques por parte de la bacteria colonica y un segundo material polimerico que tiene un umbral de ph 5 o superior, y la capa interna contiene un material polimerico de acido policarboxilico soluble en fluido intestinal o gastrointestinal.
CL2013001655A1 (es) Compuestos bifenilicos sustituidos; composicion farmaceutica; y uso en el tratamiento o prevencion de fibrosis pulmonar, renal, hepatica o cutanea.
CL2013002698A1 (es) Sistema de union vertical para un sustrato que tiene una primera y una segunda superficie principal opuestas entre si que comprende el sistema una primera y una segunda union no simetricas, extendidas a lo largo de dos lados opuestos del sustrato; metodo para fabricar un sustrato y sistema de recubrimiento de superficies.
HUE058896T2 (hu) N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
BR112014016889A8 (pt) composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
SMT201500129B (it) Formulazione di farmaco a ritenzione gastrica e sistema di somministrazione e loro metodo di preparazione usando carbonato di calcio funzionalizzato
EP3065713A4 (en) Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
DOP2016000132A (es) Sistema de administración farmacologico
BR112013011881A2 (pt) micro-organismos probióticos não replicantes que protegem contra infecções do trato respiratório superior
EP3498844A4 (en) PEPTIDE NUCLEIC ACID COMPLEX HAVING IMPROVED CELLULAR PERMEABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP2859176A4 (en) NAKABLE PACKER WITH IMPROVED ANCHORAGE AND / OR SEAL CAPACITY
CL2015001233A1 (es) Compuestos heteroaromáticos fusionados; composicion farmaceutica y el uso como ligandos d1 de dopamina en el tratamiento de enfermedades tales como esquizofrenia.
BR112015002692A2 (pt) revestimento, sistema de revestimento de barreira térmica e método para revestir uma superfície.
EP2408912A4 (en) FOXM1 PEPTIDES AND VACCINES CONTAINING THEM
EP3481381A4 (en) ORAL PHARMACEUTICAL FORM WITH ACTIVE COMPOSITION, BARRIER AND ACTIVE LAYER
WO2012042403A3 (en) Diversion pill and methods of using the same
CL2013001313A1 (es) Composicion que comprende microorganismos probióticos no replicantes para prevenir o tratar infecciones gastrointestinales
CL2017001989A1 (es) Formulación de fármaco de liberación retardada. (divisional solicitud 2795-2014)
EP2878828A4 (en) WAVE SEALING STRUCTURE AND PRIMARY COOLING MATERIAL CIRCULATION PUMP
PL3501507T3 (pl) Makrogole do aplikacji dośluzówkowej i ich zastosowania terapeutyczne
TR201001324A2 (tr) Genleştirilmiş cam kürecikler içeren ve istenilen yüzeye uygulanabilen akışkan yapıda ısı ve ses izolasyonu malzemesi
EP2507257A4 (en) MYBL2 PEPTIDES AND VACCINES THEREWITH
KR102280330B9 (ko) 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
Falk Foreword. Biologics of IBD
TH154821A (th) สารประกอบฟิวจ์ริงควิโนลิลไพร์โรโลไพริมิดิล หรือเกลือของสารนี้